AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 213 min read$IART

Integra (IART) Q3 2026 Earnings Call Transcript

Integra (IART) reported Q3 2026 adjusted EPS of $0.59, with revenue at $411.2M, impacted by Cincinnati flooding. Operating cash flow was $96M. Full-year revenue guidance was reduced by $30M due to flooding and mixed portfolio performance. Tissue Reconstruction revenue is expected to be flat. The company reduced leverage to 3.8x and completed debt refinancing, strengthening its balance sheet.

Original reporting
finance.yahoo.com
Published Oct 21, 2026, 5:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 5:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Integra (IART) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The earnings release provides fresh numbers and a guidance downgrade, creating immediate trading relevance.

02

Market read

New earnings and guidance data make the story highly relevant for traders holding or considering IART.

03

What to watch

Potential upside from upcoming SurgiMend launch and strong neurosurgery momentum may offset near‑term weakness.

Relevance 8/10Novelty 8/10Timing: post-earnings today

Background

Integra LifeSciences disclosed its Q3 2026 results, highlighting flood disruption at its Cincinnati site and a revised full‑year outlook.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra reported Q3 2026 earnings with $0.59 EPS, $411.2M revenue and cut full-year revenue guidance by $30M due to flood impact.

Expected impact

likely pressure as investors price in lower revenue outlook

Evidence & confidence

Earnings beat EPS but revenue guidance cut and operational disruption are material negative catalysts.

Market effects

Sector

Tissue reconstruction and neurosurgery segments may see mixed sentiment; peers could face similar flood‑related risks.

Regional

U.S. healthcare equipment sector may see modest pullback on guidance cuts.

Global

Limited to U.S. med‑tech investors; no broader macro effect.

Counterpoint

What could challenge this read

Despite guidance cut, cash flow strength and leverage reduction could support a short‑term bounce.

Key entities

  • company
    Integra LifeSciences

    Medical device manufacturer reporting Q3 results.

Read at source← All news

StoryIntegra LifeSciences reports Q3 2026 results, cites $7 M flood hit, completes $2.1 B refinancing and trims Q4 outlook

Also covered by

6 outlets

Related articles

OCT 21
$IARTMed

Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

gurufocus.com3 min
OCT 21
$IARTHigh

Integra Life falls as tissue reconstruction woes add to flooding worries in Q3

Integra LifeSciences (IART) shares fell to a May low after Q3 2026 results missed revenue estimates. Revenue was $411.2M, up 2% YoY but below consensus by $0.9M, impacted by a $7M headwind and weaker Tissue Reconstruction performance. Gross margin declined 500 bps to 51%, while adjusted net income rose 12% YoY to $46.4M, beating estimates by $0.03 per share. Q4 and full-year outlooks were set below consensus.

tradingview.com2 min
OCT 21
Med

Integra LifeSciences Holdings Corporation Q3 2026 Earnings Call Summary

Integra LifeSciences reported Q3 2026 earnings, citing a $7M revenue hit from Cincinnati flooding. Neurosurgery grew 6.5% organically, offsetting weaker segments. Tissue Reconstruction showed mixed results. The company refinanced $2.1B in debt. Management expects 2027 revenue to be impacted by $15M-$20M in Q1 and Q2 due to ongoing disruption. Earnings growth is projected to be supported by cost savings and a SurgiMend relaunch.

finance.yahoo.com2 min
OCT 21
$IARTMed

Why Integra LifeSciences (IART) stock is falling today

Integra LifeSciences (IART) shares fell 7.3% after reporting Q3 revenue of $411.2M, meeting expectations, and adjusted EPS of $0.59, beating estimates. The company cited plant flooding and operational disruptions, projecting Q4 revenue of $413M-$433M, below analyst estimates of $433.2M. Rising borrowing costs also weighed on investor sentiment.

financialcontent.com2 min
OCT 21
$IARTHighAI 8/10

What Integra LifeSciences (IART) Said on Its Q3 Earnings Call

Integra LifeSciences (IART) reported Q3 revenue of $304.1M, with neurosurgery growing 6.5% organically. Tissue Reconstruction revenue declined 2.2% to $107.1M. The company reaffirmed its full-year revenue outlook of $1.634B-$1.654B but reduced the midpoint by $30M. It expects 2027 revenue and EPS growth, supported by SurgiMend relaunch and PriMatrix momentum. Net debt was $1.5B at quarter-end, with leverage at 3.8x.

finance.yahoo.com2 min